Ginger for prevention of antiretroviral-induced nausea and vomiting: A randomized clinical trial

Expert Opinion on Drug Safety

Volumn 13, Issue 7, 2014, Pages 859-866

  Dabaghzadeh, Fatemeh ^a   Khalili, Hossein ^b   Dashti Khavidaki, Simin ^b   Abbasian, Ladan ^c   Moeinifard, Amir ^b  

^a KERMAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antiretroviral; Ginger; Nausea; Vomiting

Indexed keywords

CD4 ANTIGEN; EFAVIRENZ; GINGER EXTRACT; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PLACEBO; ZIDOVUDINE; ANTIRETROVIRUS AGENT; PLANT MEDICINAL PRODUCT;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CANDIDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG USE; FEMALE; GINGER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; VIRUS TRANSMISSION; VISUAL ANALOG SCALE; CLINICAL TRIAL; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; NAUSEA; VOMITING;

ADULT; ANTI-RETROVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GINGER; HIV; HIV INFECTIONS; HUMANS; MALE; NAUSEA; PLANT PREPARATIONS; VOMITING;

EID: 84902689501     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.914170     Document Type: Article

References (33)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356(9239):1423-30
2. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis 2000;30(Suppl 2):S96-S116
3. Anastasi JK, Capili B. Nausea and vomiting in HIV/AIDS. Gastroenterol Nurs 2011;34(1):15-24
4. O'Brien ME, Clark RA, Besch CL, et al. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. J Acquir Immune Defic Syndr 2003;34(4):407-14
5. O'Neil CR, Palmer AK, Coulter S, et al. Factors associated with antiretroviral medication adherence among HIV-positive adults accessing highly active antiretroviral therapy (HAART) in British Columbia, Canada. J Int Assoc Physicians AIDS Care (Chic) 2012;11(2):134-41
6. Chubineh S, McGowan J. Nausea and vomiting in HIV: a symptom review. Int J STD AIDS 2008;19(11):723-8
7. Lee LM, Henderson DK. Tolerability of postexposure antiretroviral prophylaxis for occupational exposures to HIV. Drug Saf 2001;24(8):587-97
8. Shibuyama S, Gevorkyan A, Yoo U, et al. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006;12(9):1075-90
9. White B. Ginger: an overview. Am Fam Physician 2007;75(11):1689-91
10. Ali BH, Blunden G, Tanira MO, Nemmar A. Some phytochemical, pharmacological and toxicological properties of ginger (Zingiber officinale): a review of recent research. Food Chem Toxicol 2008;46(2):409-20
11. Li M, Chen PZ, Yue QX, et al. Pungent ginger components modulates human cytochrome P450 enzymes in vitro. Acta Pharmacol Sin 2013;34(9):1237-42
12. Pertz HH, Lehmann J, Roth-Ehrang R, Elz S. Effects of ginger constituents on the gastrointestinal tract: role of cholinergic M3 and serotonergic 5-HT3 and 5-HT4 receptors. Planta Med 2011;77(10):973-8
13. Qian Q, Yue W, Chen W, et al. Effect of gingerol on substance P and NK1 receptor expression in a vomiting model of mink. Chin Med J 2010;123(4):478-84
14. Qian Q, Yue W, Wang Y, et al. Gingerol inhibits cisplatin-induced vomiting by down regulating 5-hydroxytryptamine, dopamine and substance P expression in minks. Arch Pharm Res 2009;32(4):565-73
15. Sharma S, Gupta Y. Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (Zingiber officinale). J Ethnopharmacol 1998;62(1):49-55
16. Ding M, Leach M, Bradley H. The effectiveness and safety of ginger for pregnancy-induced nausea and vomiting: a systematic review. Women Birth 2013;26(1):e26-30
17. Viljoen E. A systematic review of the effect and safety of Ginger in the treatment of pregnancy-associated nausea and vomiting. Stellenbosch University, Stellenbosch; 2012. Available from: http://hdl.handle.net/10019.1/20265
18. Mahesh R, Venkatesha Perumal R, Pandi P. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods. Pharmazie 2005;60(2):83-96
19. Akram M, Shah MI, Usmanghan K. Zingiber officinale roscoe (A medicinal plant). Pak J Nutr 2011;10:399-400
20. Sontakke S, Thawani V, Naik M. Ginger as an antiemetic in nausea and vomiting induced by chemotherapy: a randomized, cross-over, double blind study. Indian J Pharmacol 2003;35(1):32-6
21. Pillai AK, Sharma KK, Gupta YK, Bakhshi S. Anti-emetic effect of ginger powder versus placebo as an add-on therapy in children and young adults receiving high emetogenic chemotherapy. Pediatr Blood Cancer 2011;56(2):234-8
22. Ryan JL, Heckler CE, Roscoe JA, et al. Ginger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer 2012;20(7):1479-89
23. Bone M, Wilkinson D, Young J, et al. Ginger root - a new antiemetic the effect of ginger root on postoperative nausea and vomiting after major gynaecological surgery. Anaesthesia 1990;45(8):669-71
24. Nanthakomon T, Pongrojpaw D. The efficacy of ginger in prevention of postoperative nausea and vomiting after major gynecologic surgery. J Med Assoc Thai 2006;89(Suppl 4):S130-6
25. Nale R, Bhave S, Divekar D. A comparative study of ginger and other routinely used antiemetics for prevention of post operative nausea and vomiting. J Anaesthesiol Clin Pharmacol 2007;23(4):405-10
26. Chaiyakunapruk N, Kitikannakorn N, Nathisuwan S, et al. The efficacy of ginger for the prevention of postoperative nausea and vomiting: a meta-analysis. Am J Obstet Gynecol 2006;194:95-9
27. Andrews PL, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol 2014;722:108-21
28. Neuman MG, Schneider M, Nanau RM, Parry C. HIV-antiretroviral therapy induced liver, gastrointestinal, and pancreatic injury. Int J Hepatol 2012;2012:760706
29. Elzi L, Marzolini C, Furrer H, Swiss HIV Cohort Study. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. Arch Intern Med 2010;170(1):57-65
30. Mallolas J, Blanco JL, Pich J, et al. A randomized trial comparing the efficacy and tolerability of two HAART strategies at two years in antiretroviral naive patients. Rev Clin Esp 2007;207(9):427-32
31. Justesen US, Fox Z, Pedersen C, MaxCmin1 and 2 trial groups. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin Pharmacol Toxicol 2007;101(5):339-44
32. Molina JM, Andrade-Villanueva J, Echevarria J, et al. CASTLE Study Team. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008;372(9639):646-55
33. Phidisa II Writing Team for Project Phidisa. Ratsela A, Polis M, Dhlomo S, et al. A randomized factorial trial comparing 4 treatment regimens in treatment-naive HIV-infected persons with AIDS and/or a CD4 cell count <200 Cells/μ L in South Africa. J Infect Dis 2010; 202(10): 1529-37